ID
20217
Beschrijving
The purpose of this study is to determine the safety and efficacy of natalizumab in the treatment of individuals who have been diagnosed with relapsing remitting multiple sclerosis (MS). It is hoped that natalizumab will prevent certain types of white blood cells from moving out of the bloodstream into organs, including the brain, that are being damaged by autoimmune disease (a disease in which the body's own immune system attacks certain organs). These white blood cells are thought to cause inflammation that can result in lesions (small areas of damage) in the brain. These lesions are thought to be the cause of relapses and disability in MS.
Trefwoorden
Versies (2)
- 30-01-17 30-01-17 -
- 14-02-17 14-02-17 -
Geüploaded op
14 februari 2017
DOI
Voor een aanvraag inloggen.
Licentie
Creative Commons BY-NC 3.0
Model Commentaren :
Hier kunt u commentaar leveren op het model. U kunt de tekstballonnen bij de itemgroepen en items gebruiken om er specifiek commentaar op te geven.
Itemgroep Commentaren voor :
Item Commentaren voor :
U moet ingelogd zijn om formulieren te downloaden. AUB inloggen of schrijf u gratis in.
Concomitant Non-Drug Therapy CRFs Multiple Sclerosis Tysabri NCT00027300
Concomitant Non-Drug Therapy CRFs Multiple Sclerosis Tysabri NCT00027300
Similar models
Concomitant Non-Drug Therapy CRFs Multiple Sclerosis Tysabri NCT00027300
C1707479 (UMLS CUI [1,2])
C0087111 (UMLS CUI [1,2])
C0087111 (UMLS CUI [1,2])